EyePoint Pharmaceuticals Inc (NASDAQ: EYPT) stock suffered a major decline of -15.1% on 2/6/25. The shares closed at $6.62. Moreover, trading volume in this decline was unusually high at 197% of normal. The stock has been weak relative to the market over the last nine months and has declined -14.4% during the last week.
Current PriceTarget Research Rating
EyePoint Pharmaceuticals has a current Value Trend Rating of D (Negative). The Value Trend Rating reflects inconsistent signals from PTR’s two proprietary measures of a stock’s attractiveness. EyePoint Pharmaceuticals has a neutral Appreciation Score of 60 but a very low Power Rating of 13, producing the Negative Value Trend Rating.
Rating Review
In light of this highly negative price change we are reviewing our current Overall Rating of D. This review will be completed in the next several days.
Be the first to comment